Preclinical studies suggest that ROR-1 targeted therapies like the use of CAR T and BiTEs, could be effective in treating CLL and Mantle cell lymphoma (MCL) (NCT04763083) [16]. The gene discussed is ROR1; the disease is B-cell chronic lymphocytic leukemia.